NKO(R) Awarded Best Product of 2010
26 May 2010 - 9:30PM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) is proud to announce that Neptune Krill
Oil (NKO®) was awarded the prize for best product of 2010 during
the 11th Congress of "Nutrition & Sante" in Belgium.
Independent Overall Evaluation
Neptune's client Nutrisan Nutraceuticals applied for this
distinctive "Best Product" award, which involved an in-depth
evaluation of NKO® by a scientific committee represented by
renowned professors and doctors. The evaluation was based on the
efficacy, value of innovation, biochemical composition and clinical
studies supporting each product. Three finalists were chosen among
29 products and NKO® was awarded the laureate. Nutrisan
Nutraceuticals has the right to promote NKO®'s prestigious prize
for the following year. "This is yet another outstanding
achievement awarded by a respectable independent organization that
Neptune is proud of, further distinguishing NKO® from its krill oil
competitors," said Dr. Wael Massrieh, Director of R&D at
Neptune.
Neptune Shows at Vitafoods
Neptune exhibited at Vitafoods, a Global Nutraceutical Event,
which took place from May 18th to 20th, 2010, in Geneva,
Switzerland. This event attracts more than 500 exhibitors and 6000
visitors from all over the world in the nutraceutical,
cosmeceutical, functional food and functional drinks industries.
Unlike the previous five consecutive years that Neptune has been
participating at this event, there was a noticeable difference in
the awareness of NKO®. "Visitors were no longer asking the
recurrent question - what is krill oil?" noted Mrs. Catherine
Feuillarade, Executive Director of Nutraceuticals, "but were
specifically visiting Neptune's stand to find out more on NKO® and
discuss in depth the multitude of scientific and promotional
material highlighting its strengths relative to competing
products," she added. By using the intelligent strategy of
levelling the "pricing" field, Neptune successfully allowed the
driving force behind the demand to be based on the complete
portfolio of scientific evidence, intellectual property and
expertise and not just price. There was also a marked difference in
the profile of the visitors, many of which were distinguished "big
players" in the industry that met with the Neptune team. "We
believe that successful partnerships may be developed in the next
several months, following this flagship event," said Dr.
Massrieh.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About NeuroBioPharm
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither NASDAQ nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or
implied by such forward-looking statements. In addition to
statements which explicitly describe such risks and uncertainties,
readers are urged to consider statements labeled with the
terms "believes," "belief," "expects," "intends," "anticipates,"
"will," or "plans" to be uncertain and forward-looking. The
forward-looking statements contained herein are also subject
generally to other risks and uncertainties that are described
from time to time in the Company's reports filed with the
Securities and Exchange Commission and the Canadian
securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc.
Andre Godin, V.P. Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024